Dr. Roman Perez-Soler
Chairman, Department of Oncology
Montefiore Medical Center
Contact Information:
MMC Medical Park at Eastchester
1695 Eastchester Road
Bronx, NY 10461
(718) 405-8505
Overview
Dr. Roman Perez-Soler specializes in medical oncology and is the principle investigator of the Phase II L-NDDP/Platar trail for the study of pleural mesothelioma. He is considered an international cancer expert in experimental cancer therapy, and a recipient of numerous awards for his accomplishments, particularly for his contributions to lung cancer research.
Educational Background
A native of Spain, Dr. Perez-Soler graduated with a medical degree from Universidad Autonoma in Barcelona, where he also completed a residency in Internal Medicine. He completed his fellowship in Medical Oncology at the University MD Anderson Cancer Center. The M.D. Anderson center is dedicated to improving the prognosis for patients in all stages of lung and chest cancers, including mesothelioma.
Professional Highlights
Dr. Perez-Soler is Chairman of the Department of Oncology at Montefiore Medical Center. He is a professor of Medicine and Molecular Pharmacology at the Albert Einstein College of Medicine. Also, Dr. Perez-Soler is a Scientific Advisor to Easton Capital Investment Group.
Affiliations, Publications and Clinical Research
Dr. Perez-Soler serves as a member of the Executive Advisory Committee of the General Clinical Research Center. Dr. Perez-Soler has published over a hundred articles, and papers including, "Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib," published in the Cancer Chemother Pharmacol in January of 2009. He also co-authored, "Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK," and "Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene," published in Molecular Pharmacology and the Journal of Thoracic Oncology respectively.
Source
Montefiore Medical Center
Albert Einstein College of Medicine
Eastern Capital Investment Group
